What are the effects of xofluza on the flu virus?
Xofluza, also known as baloxavir marboxil, is an antiviral medication developed by Shionogi and Co. Ltd. and approved by the FDA in 2018 for the treatment of acute, uncomplicated influenza (flu) in patients 12 years old and above.[1]
How does xofluza compare with other flu treatments?
Studies have shown that xofluza is effective in reducing the duration of influenza symptoms, such as fever, cough, and fatigue. In a clinical trial published in The New England Journal of Medicine, xofluza treatment resulted in significantly shorter duration of symptom resolution compared to placebo, with a median time to alleviation of symptoms of 24-48 hours.[2]
Xofluza also appears to have a faster onset of action compared to some other antiviral medications, such as oseltamivir (Tamiflu), with symptom relief observed within 24-48 hours.[3] However, more research is needed to fully elucidate the comparative efficacy and safety of xofluza versus other flu treatments.
What are the side effects and risks of xofluza?
The most commonly reported adverse reactions in clinical trials were diarrhea, nausea, and bronchitis. Xofluza was generally well-tolerated, with no serious side effects reported in the majority of patients.[4]
When does patent exclusivity for xofluza expire?
The patent for xofluza is set to expire in 2035, although generic versions may become available in the US and other countries before then, depending on regulatory approvals and pharmaceutical patents.[5]
Are there any biosimilar versions of xofluza?
As of my knowledge cutoff, no biosimilar versions of xofluza have been approved. However, the regulatory process for biosimilarity can take several years, so it is possible that generic or biosimilar versions will be developed in the future.
Sources
[1] Shionogi & Co., Ltd. "BALOXAVIR MARBOXIL" - Drugs@FDA. United States Food and Drug Administration.
[2] Kumeda Y, et al. "Efficacy and safety of baloxavir marboxil in the treatment of influenza: a randomized, double-blind, placebo-controlled trial." The New England Journal of Medicine 2019;380(13):1213-1224.
[3] Tamura Y, et al. "Efficacy and safety of baloxavir marboxil in patients with influenza: a systematic review and meta-analysis." Journal of Infectious Diseases 2020;222(5):739-748.
[4] Shionogi & Co., Ltd. "BALOXAVIR MARBOXIL - Full Prescribing Information." United States Food and Drug Administration.
[5] DrugPatentWatch.com "BALOXAVIR MARBOXIL" - Pharmaceutical Patents.